BAT Kenya to Sell Nicotine Pouch Factory Equipment in Nairobi

BAT by 2FIRSTS.ai
Jul.30.2024
BAT Kenya to Sell Nicotine Pouch Factory Equipment in Nairobi
BAT Kenya announces decision to sell equipment at Nairobi factory due to government delay in commercializing new nicotine pouch product.

According to a recent report by Business Daily, British American Tobacco Kenya (BAT Kenya) has decided to sell the equipment from its nicotine pouch factory located in Nairobi, the capital of Kenya. The factory has been idle since it was installed nearly five years ago, as the government has not approved the commercialization permit for the new product.

 

The company announced this decision in its six-month financial report ending on June 30, 2024. The report revealed that the company's net profit decreased by 24.3% to 2.14 billion shillings (16.33 million US dollars) due to a decrease in sales and an increase in financial costs.

 

BAT announced that the company has accepted a proposal to sell the equipment of its nicotine pouch factory, marking the end of its efforts to obtain a license since 2019.

 

BAT stated in a press release that...

 

Due to ongoing regulatory uncertainty, our nicotine pouch factory's commercialization has been hindered. In order to protect shareholder value, the company has accepted an offer to sell the equipment of the nicotine pouch factory.

 

Abandoning the nicotine pouch business means that BAT will continue to rely on its tobacco business, while facing challenges such as decreasing contract tobacco farmers, increasing taxes, and expanding illegal markets.

 

According to BAT,

 

Total revenue decreased by 6%, primarily due to a decrease in export sales, a shift in consumer preferences in the domestic market, and the temporary suspension of sales of nicotine pouches.

 

In 2019, BAT launched Lyft nicotine pouches, but stopped selling them in 2020 due to government regulations classifying them as tobacco products. The company reintroduced the product as Velo in 2022, but sales were halted due to regulatory uncertainties. BAT hopes the government will acknowledge the scientific basis for modern nicotine pouches as a "scientifically validated reduced-risk alternative to traditional tobacco cigarettes.

 

British American Tobacco (BAT) stated that due to regulatory uncertainty, the company is unable to commercialize the nicotine pouch factory, resulting in idle capital in the factory and causing investment losses.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Convenience Stores Rebalance Backbar as Nicotine Pouches Outpace Cigarettes
U.S. Convenience Stores Rebalance Backbar as Nicotine Pouches Outpace Cigarettes
As cigarette volumes continue to decline, U.S. convenience-store operators are reconfiguring backbar space to accommodate modern oral nicotine products such as nicotine pouches. Industry data show nicotine pouches have become one of the fastest-growing nicotine categories while generating higher margins for retailers.
Jun.12
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai
Canada Faces Growing Debate as Youth Nicotine Pouch Use Reaches 34.8%
Canada Faces Growing Debate as Youth Nicotine Pouch Use Reaches 34.8%
New Canadian research shows that 34.8% of people aged 17 to 27 have tried nicotine pouches, up more than fourfold from 7.6% in 2022. The findings come as Conservative politicians, Alberta’s government and the tobacco industry push Ottawa to relax current restrictions on pouch sales.
Jun.12
Opinion | As EU Reviews Tobacco Rules, Experts Warn Against Overlooking Smokers’ Alternatives
Opinion | As EU Reviews Tobacco Rules, Experts Warn Against Overlooking Smokers’ Alternatives
As the European Commission reviews its tobacco and advertising rules, two experts who provided written comments to 2Firsts argue that future EU policy should not overlook adult smokers’ alternatives. Dr Garrett McGovern and Dr Carmen Escrig say regulators should weigh relative risk, adult switching, flavours, consumer behaviour and scientific uncertainty alongside youth protection.
Industry Insight
Jun.01
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13
U.S. FDA: Youth E-Cigarette Prevention Campaign Prevented About 444,000 Initiations and Reduced Illegal Vape Sales
U.S. FDA: Youth E-Cigarette Prevention Campaign Prevented About 444,000 Initiations and Reduced Illegal Vape Sales
The U.S. Food and Drug Administration (FDA) said its youth e-cigarette prevention campaign, “The Real Cost,” prevented about 444,000 U.S. youth from starting e-cigarette use between 2023 and 2024 and blocked more than $42 million in unauthorized e-cigarette sales that would have been used by youth.
Market
Jun.25